Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats.
The anabolic effect of salmon calcitonin (SCT) on skeletal tissue was examined on glucocorticoid-induced osteopenia in female rats (12 weeks old). By the administration of methylprednisolone acetate (MPA: 0.1 mg/kg, s.c., 3 times/week) for 8 weeks, histomorphometrically detectable osteopenia with the characteristics of decreased bone formation and increased bone resorption developed in proximal tibia metaphysis. Serum osteocalcin level was also decreased by MPA treatment. Subsequent treatment with SCT (10 U/kg, s.c., 5 times/week) was found to reverse once developed osteopenia with the return of the osteocalcin level, though rats were still on MPA. Histomorphometry revealed that SCT decelerated bone resorption but augmented bone formation in this osteopenic model. After a single injection of SCT (2.5 U/kg--40 U/kg, s.c.), the serum level of parathyroid hormone (PTH) which had a potent anabolic on bone formation increased in a dose-dependent manner. These results indicate that SCT has a stimulating effect on osteoblastic bone formation and this anabolic effect may at least in part be due to its indirect effect to increase endogenous PTH secretion.
Furuichi
H
H
Department of Pharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka, Japan.
Fukuyama
R
R
Izumo
N
N
Fujita
T
T
Kohno
T
T
Nakamuta
H
H
Koida
M
M
D000818:Animals; D001846:Bone Development / Q000187:drug effects*; D001851:Bone Diseases, Metabolic / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D002116:Calcitonin / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects* / Q000031:analogs & derivatives*; D000077555:Methylprednisolone Acetate; D051381:Rats; D017208:Rats, Wistar
D000077555:Methylprednisolone Acetate; C028815:salmon calcitonin; D002116:Calcitonin; D008775:Methylprednisolone